Prescription ·Strong evidence ·Reviewed May 2026
Perindopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and stable coronary artery disease. It is administered as a prodrug that is hydrolyzed in the liver to its active metabolite, perindoprilat. Once-daily dosing reflects its long duration of action.
The bottom line
Evidence rating strong. Most-documented uses: hypertension, stable coronary artery disease (reduction of cardiovascular events), reduction of risk of cardiovascular mortality and nonfatal myocardial infarction in stable cad. 3 sources indexed (2001–2019), with 6 interaction records on file.
Core mechanism
Perindopril is a prodrug converted to the active diacid perindoprilat, which inhibits angiotensin-converting enzyme. ACE inhibition blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, leading to vasodilation, reduced aldosterone secretion, and lower blood pressure. Decreased aldosterone promotes sodium and water excretion while potassium is retained, which underlies the risk of hyperkalemia. ACE inhibition also reduces the degradation of bradykinin, contributing to vasodilation as well as the characteristic dry cough and risk of angioedema.1,2
Food reduces conversion of perindopril to active perindoprilat, lowering bioavailability of the active metabolite; perindopril is therefore recommended to be taken before a meal, typically once daily in the morning. The parent drug itself is rapidly absorbed.
Nutrients this medication can lower over time, and what to replace.
ACE inhibitors can increase urinary zinc excretion and chelate zinc, potentially lowering plasma and intracellular zinc concentrations over prolonged use.
ACE inhibitors reduce angiotensin II and aldosterone, decreasing renal sodium reabsorption and promoting natriuresis, which can lower serum sodium especially with concurrent diuretic use.
Potassium supplements or potassium-containing salt substitutes can cause hyperkalemia with Perindopril.
Recommendation: Avoid unsupervised potassium supplementation; check potassium and kidney function after initiation, dose changes, or illness.
Magnesium Glycinate may add to the blood-pressure-lowering effect of Perindopril.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
L-Citrulline may add to the blood-pressure-lowering effect of Perindopril.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
ACE inhibitors such as perindopril reduce aldosterone secretion, decreasing renal potassium excretion. Adding supplemental potassium can produce clinically significant hyperkalemia, which may cause muscle weakness, paresthesias, and life-threatening cardiac arrhythmias. Risk is amplified in patients with chronic kidney disease, diabetes, advanced age, or volume depletion.
Recommendation: Avoid routine potassium supplementation while taking perindopril unless prescribed and monitored by a clinician. Also avoid potassium-containing salt substitutes. If potassium is medically required, serum potassium and renal function should be checked before starting and periodically thereafter. Report symptoms such as palpitations, severe weakness, or numbness promptly.
ACE inhibitors are associated with a dry cough thought to involve bradykinin and substance P accumulation. Small studies suggest oral or intravenous iron may reduce ACE-inhibitor-induced cough, possibly via inhibition of nitric oxide synthase. While not harmful, this interaction is generally minor; the more practical concern is that iron salts and other supplements should be spaced from medications to avoid theoretical reductions in absorption.
Recommendation: No routine avoidance is needed. If taking iron for anemia, separate iron dosing from perindopril by about 2 hours as a general practice to minimize any absorption interference. Do not start iron specifically to treat ACE-inhibitor cough without clinician advice; persistent cough should be discussed with a prescriber, as switching agents is the standard approach.
Garlic extract has modest blood-pressure-lowering properties demonstrated in meta-analyses. Combined with perindopril, the antihypertensive effects can be additive, which may benefit blood pressure control but can also increase the risk of hypotension, dizziness, and lightheadedness, particularly when standing or in volume-depleted patients.
Recommendation: Patients combining garlic supplements with perindopril should monitor blood pressure and watch for symptoms of low blood pressure such as dizziness or fainting. Inform the prescriber so that antihypertensive dosing can be adjusted if needed. Rise slowly from sitting or lying positions.
Numbered references. Citations throughout the page link here.
In patients with stable coronary disease without heart failure, perindopril 8 mg daily significantly reduced the composite of cardiovascular death, myocardial infarction, or cardiac arrest compared with placebo.
A perindopril-based regimen reduced the risk of recurrent stroke in patients with prior stroke or TIA, with greater benefit when combined with indapamide.
The product label documents hyperkalemia risk (increased with potassium supplements, potassium-sparing diuretics, and salt substitutes), dry cough, angioedema, renal effects, and a boxed warning for fetal toxicity.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
